Improving Glycemic Control and Cardiovascular
Risk with Novel Therapies

New Horizons in the Treatment and Management of Type 2 Diabetes: Individualizing Therapy with Novel Options for Improved Patient Outcomes is a 4-part series that will provide attendees with the latest information in Type 2 Diabetes Management

This is Part II of the series focusing on Exploring New Therapies in the Individualization
of Treatment in Type 2 Diabetes Management: What Do They Have to Offer?

This activity is an archive from the webinar held on March 15, 2017

This activity is valid from valid for two years, from April 1, 2017 to March 30, 2019

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Lilly, USA LLC

The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.

Upon Completion of this activity, participants will be able to:

  • Apply newly released clinical data and guidelines on combination therapies to practice regarding glycemic management in patients with T2DM

  • Examine the evidence for the use of combination regimens that include novel hyperglycemic therapies to improve glycemic control and other cardiovascular risk factors in patients with T2DM

  • Implement tailored treatment regimens for type 2 diabetes patients featuring the various additions of combination regimens over the past few years

  • Discuss recommendations for risk factor modification and adding/intensifying combination therapy in appropriate patients

Faculty: Yehuda Handelsman MD, FACP, FACE, FNLA
Medical Director & Principal Investigator
Metabolic Institute of America


Dr. Handelsman receives research grants from Amgen, Astra Zeneca, Bristol Myers-Squibb, Boehringer Ingelheim, Grifolis, Hamni, Intarcia, GlaxcSmithKline, Lexicon, Merck, Novo Nordisk, Sanofi, and Takeda. He also serves as a consultant and/or speaker for Akcea, Amarin, Amgen, Bristol Myers-Squibb, Boehringer Ingelheim, BI-Lilly, diaDeux, Eisai, Janssen, LipoScience, Merck, Novo Nordisk, Regeneron, Sanofi, Takeda, and Vivus. His presentation has been peer reviewed for bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by an educational grant from
Lilly, USA LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue